Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Gatifloxacin is a fourth generation fluoroquinolone used to treat a wide variety of infections in the body. Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family.
- Mechanism
- Curator reviewed
The bactericidal action of Gatifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
- Primary indication
- For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenesCurator reviewed · 3 structured indications
- Formula / weight
- C19H22FN3O4 · 375.3941 g/mol (avg)
- First approval
- Canada, 2001 · United States, 2010
- Brand names
- Zymar
- Zymaxid
Resolves to
XUBOMFCQGDBHNK-UHFFFAOYSA-NSMILESCOC1=C2N(C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1)C1CC1What you can answer from here — as of September 30, 2026
Which drugs share a target with Gatifloxacin, and which of those have an active Phase 3 trial?